Shares of Hologic, Inc. (NASDAQ:HOLX) have been given a consensus recommendation of “Hold” by the eighteen brokerages that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $45.00.
A number of brokerages have recently weighed in on HOLX. Needham & Company LLC restated a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Thursday, February 1st. Canaccord Genuity downgraded Hologic from a “buy” rating to a “hold” rating and cut their target price for the stock from $48.00 to $39.00 in a research note on Thursday, May 3rd. Stifel Nicolaus cut their target price on Hologic from $42.00 to $40.00 and set a “hold” rating on the stock in a research note on Thursday, May 3rd. Leerink Swann downgraded Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $48.00 to $41.00 in a research note on Thursday, May 3rd. Finally, BidaskClub raised shares of Hologic from a “sell” rating to a “hold” rating in a report on Friday, April 27th.
Get Hologic alerts:Shares of NASDAQ HOLX traded up $0.20 during midday trading on Monday, reaching $38.92. The company’s stock had a trading volume of 1,099,563 shares, compared to its average volume of 2,540,172. Hologic has a 12-month low of $35.10 and a 12-month high of $46.80. The company has a market capitalization of $10.57 billion, a PE ratio of 19.17, a PEG ratio of 1.82 and a beta of 0.87. The company has a quick ratio of 0.98, a current ratio of 1.26 and a debt-to-equity ratio of 1.13.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.53. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. The firm had revenue of $789.30 million for the quarter, compared to the consensus estimate of $781.23 million. During the same quarter in the previous year, the business earned $0.50 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. research analysts expect that Hologic will post 2.23 EPS for the current fiscal year.
In other Hologic news, SVP Allison P. Bebo sold 7,000 shares of the business’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $38.75, for a total transaction of $271,250.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Karleen Marie Oberton sold 12,196 shares of the business’s stock in a transaction on Wednesday, May 2nd. The shares were sold at an average price of $40.00, for a total transaction of $487,840.00. Following the sale, the vice president now directly owns 13,825 shares in the company, valued at approximately $553,000. The disclosure for this sale can be found here. Insiders own 0.79% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Hologic during the 1st quarter valued at $146,000. Synovus Financial Corp bought a new stake in Hologic during the 1st quarter valued at $164,000. NuWave Investment Management LLC bought a new stake in Hologic during the 4th quarter valued at $199,000. Fiduciary Trust Co. bought a new stake in Hologic during the 4th quarter valued at $208,000. Finally, Advisor Partners LLC bought a new stake in Hologic during the 4th quarter valued at $209,000. 99.80% of the stock is currently owned by institutional investors and hedge funds.
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
No comments:
Post a Comment